TapewireFind a company

person · Reporting owner

Nielsen Jack

Disclosed activity across 8 companies

Tapewire entity
90378
SEC CIK
0001602402

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
ALX ONCOLOGY HOLDINGS INCALXO · Entity 6040Director · 10% ownerJune 20, 2023June 22, 2023
Aligos Therapeutics, Inc.ALGS · Entity 7352DirectorFebruary 27, 2024February 28, 2024
Apollo Endosurgery, Inc.APEN · Entity 114713DirectorDecember 29, 2016December 29, 2016
Crinetics Pharmaceuticals, Inc.CRNX · Entity 3579DirectorJune 21, 2019June 25, 2019
Harmony Biosciences Holdings, Inc.HRMY · Entity 4381DirectorMay 29, 2024May 31, 2024
IO Biotech, Inc.IOBT · Entity 8764DirectorJune 08, 2023June 13, 2023
Instil Bio, Inc.TIL · Entity 7177DirectorJune 14, 2023January 10, 2024
REATA PHARMACEUTICALS INCRETA · Entity 12293DirectorJune 10, 2021June 14, 2021

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ALX ONCOLOGY HOLDINGS INC

Report date June 20, 2023 · Filed June 22, 2023

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.14 · Expires 2033-06-19Direct20,200 Reported balance After 2023-06-20 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2023-06-20 · Grant · Acquired 20,200 · Balance 20,200

F1: Shares subject to the option vest in 12 equal monthly installments on the 20th day of the month, or if earlier, the day immediately before the day of the next annual meeting of stockholders.

Filing footnotes · ownership attribution and instrument terms

F1: Shares subject to the option vest in 12 equal monthly installments on the 20th day of the month, or if earlier, the day immediately before the day of the next annual meeting of stockholders.

Aligos Therapeutics, Inc.

Report date February 27, 2024 · Filed February 28, 2024

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.58 · Expires 2031-06-17Direct0 Reported balance After 2024-02-27 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2024-02-27 · Disposition to issuer · Disposed 15,000 · Balance 0

F1: On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 15,000 of the issuer's shares granted to the reporting person on June 17, 2021. In exchange, on February 28, 2024, the reporting person received a replacement option, for 4,411 shares, having an exercise price of $0.96 per share.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.96 · Expires 2031-06-17Direct4,411 Reported balance After 2024-02-28 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2024-02-28 · Grant · Acquired 4,411 · Balance 4,411

F1: On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 15,000 of the issuer's shares granted to the reporting person on June 17, 2021. In exchange, on February 28, 2024, the reporting person received a replacement option, for 4,411 shares, having an exercise price of $0.96 per share.

F2: The shares subject to the option will vest and become exercisable on the one year anniversary of the date of grant, subject to the reporting person's continued service with the issuer through such one year anniversary.

Filing footnotes · ownership attribution and instrument terms

F1: On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 15,000 of the issuer's shares granted to the reporting person on June 17, 2021. In exchange, on February 28, 2024, the reporting person received a replacement option, for 4,411 shares, having an exercise price of $0.96 per share.

F2: The shares subject to the option will vest and become exercisable on the one year anniversary of the date of grant, subject to the reporting person's continued service with the issuer through such one year anniversary.

Apollo Endosurgery, Inc.

Report date December 29, 2016 · Filed December 29, 2016

This filing explicitly reported no securities owned.

Crinetics Pharmaceuticals, Inc.

Report date June 21, 2019 · Filed June 25, 2019

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.24 · Expires 2029-06-20Direct12,500 Reported balance After 2019-06-21 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2019-06-21 · Grant · Acquired 12,500 · Balance 12,500

F1: The entire number of shares subject to this option become fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The entire number of shares subject to this option become fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.

Harmony Biosciences Holdings, Inc.

Report date May 29, 2024 · Filed May 31, 2024

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $29.33 · Expires 2034-05-29Direct6,336 Reported balance After 2024-05-29 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2024-05-29 · Grant · Acquired 6,336 · Balance 6,336

F1: The stock option shall vest in full on the earlier to occur of (i) May 29, 2025 and (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The stock option shall vest in full on the earlier to occur of (i) May 29, 2025 and (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date.

IO Biotech, Inc.

Report date June 08, 2023 · Filed June 13, 2023

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.08 · Expires 2033-06-08Direct41,533 Reported balance After 2023-06-08 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2023-06-08 · Grant · Acquired 41,533 · Balance 41,533

F1: These options vest on June 8, 2024, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control.

Filing footnotes · ownership attribution and instrument terms

F1: These options vest on June 8, 2024, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control.

Instil Bio, Inc.

Report date June 14, 2023 · Filed January 10, 2024

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.18 · Expires 2033-06-13Direct1,500 Reported balance After 2023-06-14 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2023-06-14 · Grant · Acquired 1,500 · Balance 1,500

F1: The option will vest in 12 equal monthly installments commencing on July 14, 2023, subject to the Report Person's continued service as a director through the vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The option will vest in 12 equal monthly installments commencing on July 14, 2023, subject to the Report Person's continued service as a director through the vesting date.

REATA PHARMACEUTICALS INC

Report date June 10, 2021 · Filed June 14, 2021

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $146.01 · Expires 2031-06-10Direct5,000 Reported balance After 2021-06-10 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2021-06-10 · Grant · Acquired 5,000 · Balance 5,000

F1: The options vest in 4 equal installments on September 10, 2021, December 10, 2021, March 10, 2022, and June 10, 2022, subject to continued service through each vesting date.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $146.01 · Expires 2031-06-10Direct1,201 Reported balance After 2021-06-10 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2021-06-10 · Grant · Acquired 1,201 · Balance 1,201

F3: This option was issued to the reporting person pursuant to the Reata Non-Employee Director Compensation Policy in lieu of future director fees of $100,000.

F2: The options vest in the following installments: 300 shares on September 10, 2021, December 10, 2021 and March 10, 2022, respectively, and 301 shares June 10, 2022, subject to continued service through each vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The options vest in 4 equal installments on September 10, 2021, December 10, 2021, March 10, 2022, and June 10, 2022, subject to continued service through each vesting date.

F2: The options vest in the following installments: 300 shares on September 10, 2021, December 10, 2021 and March 10, 2022, respectively, and 301 shares June 10, 2022, subject to continued service through each vesting date.

F3: This option was issued to the reporting person pursuant to the Reata Non-Employee Director Compensation Policy in lieu of future director fees of $100,000.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
May 29, 2024 Filed May 31, 2024 08:54 UTC Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 GrantStock Option · Derivative 6,336 $0.00 Strike: $29.33 $0.00
Disclosure

SEC source: 0001415889-24-014966 · form4-05312024_120509.xml · derivative · entry 1

Nielsen Jack · CIK 0001602402 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,336

Underlying: Common Stock · 6,336 shares

Expires 2034-05-29

F1 · derivative.exercise_date: The stock option shall vest in full on the earlier to occur of (i) May 29, 2025 and (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date.

Read SEC document
February 28, 2024 Filed Feb 28, 2024 22:30 UTC Aligos Therapeutics, Inc. ALGS · Entity 7352 GrantStock Option (Right to Buy) · Derivative 4,411 $0.00 Strike: $0.96 $0.00
Disclosure

SEC source: 0001610717-24-000096 · form4.xml · derivative · entry 2

Nielsen Jack · CIK 0001602402 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,411

Underlying: Common Stock · 4,411 shares

Expires 2031-06-17

F1 · price: On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 15,000 of the issuer's shares granted to the reporting person on June 17, 2021. In exchange, on February 28, 2024, the reporting person received a replacement option, for 4,411 shares, having an exercise price of $0.96 per share.

F2 · derivative.exercise_date: The shares subject to the option will vest and become exercisable on the one year anniversary of the date of grant, subject to the reporting person's continued service with the issuer through such one year anniversary.

Read SEC document
February 27, 2024 Filed Feb 28, 2024 22:30 UTC Aligos Therapeutics, Inc. ALGS · Entity 7352 Disposition to issuerStock Option (Right to Buy) · Derivative 15,000 $0.00 Strike: $26.58 $0.00
Disclosure

SEC source: 0001610717-24-000096 · form4.xml · derivative · entry 1

Nielsen Jack · CIK 0001602402 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,000 shares

Expires 2031-06-17

F1 · price: On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 15,000 of the issuer's shares granted to the reporting person on June 17, 2021. In exchange, on February 28, 2024, the reporting person received a replacement option, for 4,411 shares, having an exercise price of $0.96 per share.

Read SEC document
July 20, 2023 Filed Jul 21, 2023 23:23 UTC Aligos Therapeutics, Inc. ALGS · Entity 7352 GrantStock Option (Right to Buy) · Derivative 20,000 $0.00 Strike: $1.00 $0.00
Disclosure

SEC source: 0001610717-23-000216 · form4.xml · derivative · entry 1

Nielsen Jack · CIK 0001602402 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2033-07-20

F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2024 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date.

Read SEC document
June 20, 2023 Filed Jun 22, 2023 20:51 UTC ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 GrantStock Option (right to buy) · Derivative 20,200 $0.00 Strike: $8.14 $0.00
Disclosure

SEC source: 0001209191-23-039109 · doc4.xml · derivative · entry 1

Nielsen Jack · CIK 0001602402 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,200

Underlying: Common Stock · 20,200 shares

Expires 2033-06-19

F1 · derivative.exercise_date: Shares subject to the option vest in 12 equal monthly installments on the 20th day of the month, or if earlier, the day immediately before the day of the next annual meeting of stockholders.

Read SEC document
June 14, 2023 Filed Jan 10, 2024 19:48 UTC Instil Bio, Inc. TIL · Entity 7177 GrantStock Option (Right to Buy) · Derivative 1,500 $0.00 Strike: $11.18 $0.00
Disclosure

SEC source: 0001789769-24-000006 · wk-form4_1704934071.xml · derivative · entry 1

Nielsen Jack · CIK 0001602402 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,500

Underlying: Common Stock · 1,500 shares

Expires 2033-06-13

F1 · derivative.exercise_date: The option will vest in 12 equal monthly installments commencing on July 14, 2023, subject to the Report Person's continued service as a director through the vesting date.

Read SEC document
June 08, 2023 Filed Jun 13, 2023 23:54 UTC IO Biotech, Inc. IOBT · Entity 8764 GrantStock Option (Right to Buy) · Derivative 41,533 $0.00 Strike: $2.08 $0.00
Disclosure

SEC source: 0001140361-23-029697 · form4.xml · derivative · entry 1

Nielsen Jack · CIK 0001602402 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,533

Underlying: Common Stock · 41,533 shares

Expires 2033-06-08

F1 · derivative.exercise_date: These options vest on June 8, 2024, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control.

Read SEC document
May 25, 2023 Filed May 26, 2023 17:25 UTC Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 GrantStock Option · Derivative 5,224 $0.00 Strike: $35.99 $0.00
Disclosure

SEC source: 0001415889-23-008873 · form4-05262023_090505.xml · derivative · entry 1

Nielsen Jack · CIK 0001602402 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,224

Underlying: Common Stock · 5,224 shares

Expires 2033-05-25

F1 · derivative.exercise_date: The stock option shall vest in full on the earlier to occur of (i) May 25, 2024 and (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date.

Read SEC document
December 14, 2022 Filed Dec 16, 2022 19:15 UTC Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 SaleCommon Stock 2,834 $59.96 $169,926.64
Disclosure

SEC source: 0001415889-22-012646 · form4-12172022_121244.xml · nonDerivative · entry 1

Nielsen Jack · CIK 0001602402 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,571,024

F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2022.

F2 · price: The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $59.88 to $60.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (2) to this Form 4.

F3 · ownership.nature: The shares are held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. As a managing member of Vivo Capital VIII, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein.

Read SEC document
December 09, 2022 Filed Dec 9, 2022 20:34 UTC Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 SaleCommon Stock 9,847 $59.89 $589,736.83
Disclosure

SEC source: 0001415889-22-012358 · form4-12102022_011258.xml · nonDerivative · entry 3

Nielsen Jack · CIK 0001602402 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,573,858

F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2022.

F5 · price: The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $59.88 to $60.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (5) to this Form 4.

F3 · ownership.nature: The shares are held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. As a managing member of Vivo Capital VIII, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein.

Read SEC document
December 08, 2022 Filed Dec 9, 2022 20:34 UTC Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 SaleCommon Stock 36,878 $59.90 $2,208,992.20
Disclosure

SEC source: 0001415889-22-012358 · form4-12102022_011258.xml · nonDerivative · entry 2

Nielsen Jack · CIK 0001602402 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,583,705

F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2022.

F4 · price: The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $59.88 to $60.11, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (4) to this Form 4.

F3 · ownership.nature: The shares are held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. As a managing member of Vivo Capital VIII, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein.

Read SEC document
December 07, 2022 Filed Dec 9, 2022 20:34 UTC Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 SaleCommon Stock 64,026 $60.35 $3,863,969.10
Disclosure

SEC source: 0001415889-22-012358 · form4-12102022_011258.xml · nonDerivative · entry 1

Nielsen Jack · CIK 0001602402 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,620,583

F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2022.

F2 · price: The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $59.93 to $60.54, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (2) to this Form 4.

F3 · ownership.nature: The shares are held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. As a managing member of Vivo Capital VIII, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein.

Read SEC document
December 01, 2022 Filed Dec 1, 2022 19:52 UTC Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 SaleCommon Stock 65,652 $60.00 $3,939,120.00
Disclosure

SEC source: 0001415889-22-011913 · form4-12022022_121234.xml · nonDerivative · entry 3

Nielsen Jack · CIK 0001602402 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,684,609

F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2022.

F5 · price: The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $59.88 to $60.38, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (5) to this Form 4.

F3 · ownership.nature: The shares are held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. As a managing member of Vivo Capital VIII, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein.

Read SEC document
November 30, 2022 Filed Dec 1, 2022 19:52 UTC Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 SaleCommon Stock 42,667 $58.93 $2,514,366.31
Disclosure

SEC source: 0001415889-22-011913 · form4-12022022_121234.xml · nonDerivative · entry 2

Nielsen Jack · CIK 0001602402 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,750,261

F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2022.

F4 · price: The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $57.5 to $59.84, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (4) to this Form 4.

F3 · ownership.nature: The shares are held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. As a managing member of Vivo Capital VIII, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein.

Read SEC document
November 29, 2022 Filed Dec 1, 2022 19:52 UTC Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 SaleCommon Stock 21,333 $57.82 $1,233,474.06
Disclosure

SEC source: 0001415889-22-011913 · form4-12022022_121234.xml · nonDerivative · entry 1

Nielsen Jack · CIK 0001602402 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,792,928

F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2022.

F2 · price: The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $57.21 to $58.38, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (2) to this Form 4.

F3 · ownership.nature: The shares are held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. As a managing member of Vivo Capital VIII, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein.

Read SEC document
November 22, 2022 Filed Nov 22, 2022 20:57 UTC Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 SaleCommon Stock 31,902 $57.60 $1,837,555.20
Disclosure

SEC source: 0001104659-22-121399 · tm2230208-4_4seq1.xml · nonDerivative · entry 3

Nielsen Jack · CIK 0001602402 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,814,261

F2 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2022

F5 · price: The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $56.21 to $58.14, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (5) to this Form 4.

F1 · ownership.nature: The shares are held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. As a managing member of Vivo Capital VIII, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein.

Read SEC document
November 21, 2022 Filed Nov 22, 2022 20:57 UTC Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 SaleCommon Stock 24,898 $57.08 $1,421,177.84
Disclosure

SEC source: 0001104659-22-121399 · tm2230208-4_4seq1.xml · nonDerivative · entry 2

Nielsen Jack · CIK 0001602402 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,846,163

F2 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2022

F4 · price: The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $55.89 to $57.61, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (4) to this Form 4.

F1 · ownership.nature: The shares are held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. As a managing member of Vivo Capital VIII, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein.

Read SEC document
November 18, 2022 Filed Nov 22, 2022 20:57 UTC Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 SaleCommon Stock 20,800 $57.00 $1,185,600.00
Disclosure

SEC source: 0001104659-22-121399 · tm2230208-4_4seq1.xml · nonDerivative · entry 1

Nielsen Jack · CIK 0001602402 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,871,061

F2 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2022

F3 · price: The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $56.4 to $57.5, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (3) to this Form 4.

F1 · ownership.nature: The shares are held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. As a managing member of Vivo Capital VIII, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein.

Read SEC document
November 15, 2022 Filed Nov 15, 2022 18:26 UTC Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 SaleCommon Stock 62,933 $56.80 $3,574,594.40
Disclosure

SEC source: 0001104659-22-119223 · tm2230208-2_4seq1.xml · nonDerivative · entry 3

Nielsen Jack · CIK 0001602402 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,891,861

F2 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2022.

F5 · price: The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $55.91 to $61.22, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (5) to this Form 4.

F1 · ownership.nature: The shares are held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. As a managing member of Vivo Capital VIII, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein.

Read SEC document
November 14, 2022 Filed Nov 15, 2022 18:26 UTC Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 SaleCommon Stock 58,667 $58.70 $3,443,752.90
Disclosure

SEC source: 0001104659-22-119223 · tm2230208-2_4seq1.xml · nonDerivative · entry 2

Nielsen Jack · CIK 0001602402 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,954,794

F2 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2022.

F4 · price: The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $56.82 to $59.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (4) to this Form 4.

F1 · ownership.nature: The shares are held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. As a managing member of Vivo Capital VIII, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein.

Read SEC document
November 11, 2022 Filed Nov 15, 2022 18:26 UTC Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 SaleCommon Stock 36,800 $57.14 $2,102,752.00
Disclosure

SEC source: 0001104659-22-119223 · tm2230208-2_4seq1.xml · nonDerivative · entry 1

Nielsen Jack · CIK 0001602402 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 3,013,461

F2 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2022.

F3 · price: The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $55.89 to $58.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (3) to this Form 4.

F1 · ownership.nature: The shares are held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. As a managing member of Vivo Capital VIII, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein.

Read SEC document
August 08, 2022 Filed Aug 8, 2022 20:18 UTC Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 SaleCommon Stock 75,000 $53.56 $4,017,000.00
Disclosure

SEC source: 0001104659-22-087481 · tm2222520-2_4seq1.xml · nonDerivative · entry 3

Nielsen Jack · CIK 0001602402 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 3,050,261

F4 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $52.40 to $54.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (4) to this Form 4.

F1 · ownership.nature: The shares are held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. As a managing member of Vivo Capital VIII, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein.

Read SEC document
August 05, 2022 Filed Aug 8, 2022 20:18 UTC Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 SaleCommon Stock 115,000 $52.42 $6,028,300.00
Disclosure

SEC source: 0001104659-22-087481 · tm2222520-2_4seq1.xml · nonDerivative · entry 2

Nielsen Jack · CIK 0001602402 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 3,125,261

F3 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $51.50 to $53.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (3) to this Form 4.

F1 · ownership.nature: The shares are held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. As a managing member of Vivo Capital VIII, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein.

Read SEC document
August 04, 2022 Filed Aug 8, 2022 20:18 UTC Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 SaleCommon Stock 60,000 $52.30 $3,138,000.00
Disclosure

SEC source: 0001104659-22-087481 · tm2222520-2_4seq1.xml · nonDerivative · entry 1

Nielsen Jack · CIK 0001602402 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 3,240,261

F2 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $51.70 to $52.72, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (2) to this Form 4.

F1 · ownership.nature: The shares are held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. As a managing member of Vivo Capital VIII, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein.

Read SEC document
August 02, 2022 Filed Aug 3, 2022 16:16 UTC Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 SaleCommon Stock 75,117 $55.22 $4,147,960.74
Disclosure

SEC source: 0001104659-22-085635 · tm2222520-1_4seq1.xml · nonDerivative · entry 1

Nielsen Jack · CIK 0001602402 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 3,300,261

F2 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021.

F3 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $55.00 to $55.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (3) to this Form 4.

F1 · ownership.nature: The shares are held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. As a managing member of Vivo Capital VIII, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein.

Read SEC document
July 18, 2022 Filed Jul 20, 2022 18:26 UTC Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 SaleCommon Stock 40,087 $55.19 $2,212,401.53
Disclosure

SEC source: 0001104659-22-081249 · tm2220923-3_4seq1.xml · nonDerivative · entry 1

Nielsen Jack · CIK 0001602402 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 3,375,378

F2 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021.

F3 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $55.00 to $55.75, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (3) to this Form 4.

F1 · ownership.nature: The shares are held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. As a managing member of Vivo Capital VIII, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein.

Read SEC document
July 13, 2022 Filed Jul 15, 2022 21:18 UTC Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 SaleCommon Stock 5,773 $55.04 $317,745.92
Disclosure

SEC source: 0001104659-22-080294 · tm2220923-2_4seq1.xml · nonDerivative · entry 1

Nielsen Jack · CIK 0001602402 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 3,415,465

F2 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021.

F3 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $55.00 to $55.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (3) to this Form 4.

F1 · ownership.nature: The shares are held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. As a managing member of Vivo Capital VIII, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein.

Read SEC document
July 11, 2022 Filed Jul 12, 2022 18:37 UTC Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 SaleCommon Stock 3,058 $55.01 $168,220.58
Disclosure

SEC source: 0001104659-22-079272 · tm2220923-1_4seq1.xml · nonDerivative · entry 2

Nielsen Jack · CIK 0001602402 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 3,421,238

F2 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021.

F4 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $55.00 to $55.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (4) to this Form 4.

F1 · ownership.nature: The shares are held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. As a managing member of Vivo Capital VIII, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein.

Read SEC document
July 08, 2022 Filed Jul 12, 2022 18:37 UTC Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 SaleCommon Stock 7,710 $55.07 $424,589.70
Disclosure

SEC source: 0001104659-22-079272 · tm2220923-1_4seq1.xml · nonDerivative · entry 1

Nielsen Jack · CIK 0001602402 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 3,424,296

F2 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021.

F3 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $55.00 to $55.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (3) to this Form 4.

F1 · ownership.nature: The shares are held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. As a managing member of Vivo Capital VIII, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein.

Read SEC document
July 07, 2022 Filed Jul 7, 2022 18:22 UTC Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 SaleCommon Stock 180,838 $56.01 $10,128,736.38
Disclosure

SEC source: 0001104659-22-078112 · tm2220313-2_4seq1.xml · nonDerivative · entry 3

Nielsen Jack · CIK 0001602402 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 3,432,006

F2 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021.

F5 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $55.00 to $56.69, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (5) to this Form 4.

F1 · ownership.nature: The shares are held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. As a managing member of Vivo Capital VIII, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein.

Read SEC document
July 06, 2022 Filed Jul 7, 2022 18:22 UTC Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 SaleCommon Stock 87,417 $55.26 $4,830,663.42
Disclosure

SEC source: 0001104659-22-078112 · tm2220313-2_4seq1.xml · nonDerivative · entry 2

Nielsen Jack · CIK 0001602402 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 3,612,844

F2 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021.

F4 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $55.00 to $55.52, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (4) to this Form 4.

F1 · ownership.nature: The shares are held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. As a managing member of Vivo Capital VIII, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein.

Read SEC document
July 05, 2022 Filed Jul 7, 2022 18:22 UTC Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 SaleCommon Stock 32,486 $52.27 $1,698,043.22
Disclosure

SEC source: 0001104659-22-078112 · tm2220313-2_4seq1.xml · nonDerivative · entry 1

Nielsen Jack · CIK 0001602402 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 3,700,261

F2 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021.

F3 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $52.00 to $52.68, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (3) to this Form 4.

F1 · ownership.nature: The shares are held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. As a managing member of Vivo Capital VIII, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein.

Read SEC document
July 01, 2022 Filed Jul 1, 2022 18:50 UTC Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 SaleCommon Stock 11,038 $52.04 $574,417.52
Disclosure

SEC source: 0001104659-22-076951 · tm2220313-1_4seq1.xml · nonDerivative · entry 2

Nielsen Jack · CIK 0001602402 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 3,732,747

F2 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021.

F4 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $52.00 to $52.11, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (4) to this Form 4.

F1 · ownership.nature: The shares are held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. As a managing member of Vivo Capital VIII, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein.

Read SEC document
June 29, 2022 Filed Jul 1, 2022 18:50 UTC Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 SaleCommon Stock 3,533 $52.20 $184,422.60
Disclosure

SEC source: 0001104659-22-076951 · tm2220313-1_4seq1.xml · nonDerivative · entry 1

Nielsen Jack · CIK 0001602402 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 3,743,785

F2 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021.

F3 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $52.00 to $52.45, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (3) to this Form 4.

F1 · ownership.nature: The shares are held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. As a managing member of Vivo Capital VIII, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein.

Read SEC document
June 28, 2022 Filed Jun 28, 2022 18:34 UTC Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 SaleCommon Stock 2,726 $52.10 $142,024.60
Disclosure

SEC source: 0001104659-22-075352 · tm2219926-1_4seq1.xml · nonDerivative · entry 3

Nielsen Jack · CIK 0001602402 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 3,747,318

F2 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021.

F5 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $52.00 to $52.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (5) to this Form 4.

F1 · ownership.nature: The shares are held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. As a managing member of Vivo Capital VIII, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein.

Read SEC document
June 27, 2022 Filed Jun 28, 2022 18:34 UTC Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 SaleCommon Stock 86,209 $52.37 $4,514,765.33
Disclosure

SEC source: 0001104659-22-075352 · tm2219926-1_4seq1.xml · nonDerivative · entry 2

Nielsen Jack · CIK 0001602402 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 3,750,044

F2 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021.

F4 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $52.00 to $52.65, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (4) to this Form 4.

F1 · ownership.nature: The shares are held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. As a managing member of Vivo Capital VIII, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein.

Read SEC document
June 24, 2022 Filed Jun 28, 2022 18:34 UTC Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 SaleCommon Stock 11,528 $52.06 $600,147.68
Disclosure

SEC source: 0001104659-22-075352 · tm2219926-1_4seq1.xml · nonDerivative · entry 1

Nielsen Jack · CIK 0001602402 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 3,836,253

F2 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021.

F3 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $52.00 to $52.32, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (3) to this Form 4.

F1 · ownership.nature: The shares are held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. As a managing member of Vivo Capital VIII, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein.

Read SEC document
June 23, 2022 Filed Jun 27, 2022 20:13 UTC Aligos Therapeutics, Inc. ALGS · Entity 7352 GrantStock Option (Right to Buy) · Derivative 15,000 $0.00 Strike: $1.34 $0.00
Disclosure

SEC source: 0001567619-22-013389 · doc1.xml · derivative · entry 1

Nielsen Jack · CIK 0001602402 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2032-06-23

F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2023 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date.

Read SEC document
June 15, 2022 Filed Jun 17, 2022 01:25 UTC ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 GrantStock Option (right to buy) · Derivative 12,004 $0.00 Strike: $6.67 $0.00
Disclosure

SEC source: 0001209191-22-037677 · doc4.xml · derivative · entry 1

Nielsen Jack · CIK 0001602402 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,004

Underlying: Common Stock · 12,004 shares

Expires 2032-06-14

F1 · derivative.exercise_date: Shares subject to the option vest in 12 equal monthly installments on the same day of the month as the grant date, or if earlier, the day immediately before the day of the next annual meeting of stockholders.

Read SEC document
May 26, 2022 Filed May 31, 2022 23:34 UTC IO Biotech, Inc. IOBT · Entity 8764 GrantStock Option (Right to Buy) · Derivative 23,885 $0.00 Strike: $4.85 $0.00
Disclosure

SEC source: 0001567619-22-011959 · doc1.xml · derivative · entry 1

Nielsen Jack · CIK 0001602402 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,885

Underlying: Common Stock · 23,885 shares

Expires 2032-05-26

F1 · derivative.exercise_date: These options vest on May 26, 2023, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control.

Read SEC document
May 20, 2022 Filed May 24, 2022 16:16 UTC Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 GrantStock Option · Derivative 4,742 $0.00 Strike: $41.33 $0.00
Disclosure

SEC source: 0001104659-22-064247 · tm2216688-3_4seq1.xml · derivative · entry 1

Nielsen Jack · CIK 0001602402 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,742

Underlying: Common Stock · 4,742 shares

Expires 2032-05-20

F1 · derivative.exercise_date: The stock option shall vest in full on the earlier to occur of (i) May 20, 2023 and (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date.

Read SEC document
May 20, 2022 Filed May 25, 2022 18:02 UTC Instil Bio, Inc. TIL · Entity 7177 GrantEmployee Stock Option (right to buy) · Derivative 30,000 $0.00 Strike: $7.27 $0.00
Disclosure

SEC source: 0001789769-22-000051 · wf-form4_165351614718058.xml · derivative · entry 1

Nielsen Jack · CIK 0001602402 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2032-05-19

F1 · derivative.exercise_date: The option will vest in 12 equal monthly installments commencing on June 20, 2022, subject to the Report Person's continued service as a director through the vesting date.

Read SEC document
April 21, 2022 Filed Apr 25, 2022 19:51 UTC Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 SaleCommon Stock 6,554 $52.19 $342,053.26
Disclosure

SEC source: 0001104659-22-049788 · tm2211710-6_4seq1.xml · nonDerivative · entry 1

Nielsen Jack · CIK 0001602402 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 3,847,781

F2 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021.

F3 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $52.00 to $52.75, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (3) to this Form 4.

F1 · ownership.nature: The shares are held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. As a managing member of Vivo Capital VIII, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein.

Read SEC document
April 20, 2022 Filed Apr 20, 2022 19:58 UTC Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 SaleCommon Stock 30,177 $52.14 $1,573,428.78
Disclosure

SEC source: 0001104659-22-047993 · tm2211710-5_4seq1.xml · nonDerivative · entry 3

Nielsen Jack · CIK 0001602402 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 3,854,335

F2 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021.

F5 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $52.00 to $53.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (5) to this Form 4.

F1 · ownership.nature: The shares are held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. As a managing member of Vivo Capital VIII, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein.

Read SEC document
April 19, 2022 Filed Apr 20, 2022 19:58 UTC Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 SaleCommon Stock 97,886 $52.35 $5,124,332.10
Disclosure

SEC source: 0001104659-22-047993 · tm2211710-5_4seq1.xml · nonDerivative · entry 2

Nielsen Jack · CIK 0001602402 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 3,884,512

F2 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021.

F4 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $52.00 to $53.35, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (4) to this Form 4.

F1 · ownership.nature: The shares are held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. As a managing member of Vivo Capital VIII, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein.

Read SEC document
April 18, 2022 Filed Apr 20, 2022 19:58 UTC Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 SaleCommon Stock 4,195 $52.14 $218,727.30
Disclosure

SEC source: 0001104659-22-047993 · tm2211710-5_4seq1.xml · nonDerivative · entry 1

Nielsen Jack · CIK 0001602402 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 3,982,398

F2 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021.

F3 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $52.00 to $52.56, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (3) to this Form 4.

F1 · ownership.nature: The shares are held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. As a managing member of Vivo Capital VIII, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein.

Read SEC document
April 14, 2022 Filed Apr 14, 2022 19:26 UTC Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 SaleCommon Stock 13,668 $52.08 $711,829.44
Disclosure

SEC source: 0001104659-22-046146 · tm2211710-4_4seq1.xml · nonDerivative · entry 5

Nielsen Jack · CIK 0001602402 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 3,986,593

F3 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021.

F6 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $52.00 to $52.35, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (6) to this Form 4.

F2 · ownership.nature: The shares are held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. As a managing member of Vivo Capital VIII, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein.

Read SEC document
April 13, 2022 Filed Apr 14, 2022 19:26 UTC Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 SaleCommon Stock 75,465 $51.15 $3,860,034.75
Disclosure

SEC source: 0001104659-22-046146 · tm2211710-4_4seq1.xml · nonDerivative · entry 4

Nielsen Jack · CIK 0001602402 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 4,000,261

F3 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021.

F5 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $50.00 to $52.18, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (5) to this Form 4.

F2 · ownership.nature: The shares are held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. As a managing member of Vivo Capital VIII, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein.

Read SEC document
April 13, 2022 Filed Apr 14, 2022 19:26 UTC Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 SaleCommon Stock 10,741 $51.15 $549,402.15
Disclosure

SEC source: 0001104659-22-046146 · tm2211710-4_4seq1.xml · nonDerivative · entry 3

Nielsen Jack · CIK 0001602402 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

F3 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021.

F5 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $50.00 to $52.18, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (5) to this Form 4.

F1 · ownership.nature: The shares are held of record by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the General Partner of Vivo Capital Fund IX, L.P. As a managing member of Vivo Capital IX, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund IX, L.P with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein.

Read SEC document
April 12, 2022 Filed Apr 14, 2022 19:26 UTC Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 SaleCommon Stock 17,469 $50.05 $874,323.45
Disclosure

SEC source: 0001104659-22-046146 · tm2211710-4_4seq1.xml · nonDerivative · entry 2

Nielsen Jack · CIK 0001602402 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 4,075,726

F3 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021.

F4 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $50.00 to $50.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (4) to this Form 4.

F2 · ownership.nature: The shares are held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. As a managing member of Vivo Capital VIII, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.